Moving Forward: First Data Transferred Into The HARMONY Big
HARMONY Anonymization Concept Reconciles Data Quality, Safety, ...
The “Summary report of the Heads of Medicines Agencies” ...
EHA and HARMONY organize the 2nd meeting for the HM Key Opinion ...
HARMONY Patient Cluster discussed the prospective outlook of ...
HARMONY Receives Prize Awarded by the Spanish Health Informatics ...
Thank you for your interest in the HARMONY Alliance. '2018
Henrik Edgren, Medisapiens, HARMONY Partner, explains how the ...
Interview with Dr. Guillermo Sanz, Co-Chair HARMONY Alliance: ...
Ken Mills of Queens University Belfast, HARMONY Associated
New IMI project launched: EHDEN, European Health Data & Evidence ...
Maurille Feudjo Tepie of HARMONY Partner AMGEN, addressing BigData ...
Jonathan Pearce, Lymphoma Coalition, about the importance of ...
HARMONY Partner Celgene facilitated an awareness meeting explaining ...
Special report Financial Times: EU’s Innovative Medicines ...
Ana Heredia Casanoves, GMV explains the HARMONY Data Platform ...
Prof Andrea Manca, University of York, elaborates on
HARMONY & ASH2018: 60th Annual Meeting of the American Society ...
HARMONY young talent presenting at the IMI 10th Anniversary
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands